Loomis, Sayles & Company
YMAB

Loomis, Sayles & Company’s Y-mAbs Therapeutics YMAB Stock Holding History

Loomis, Sayles & Company’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-782,084
Closed -$23.6M – 928
2021
Q1 		$23.6M Sell
782,084
-2,198
-0.3% -$90.1K 0.03% 269
2020
Q4 		$38.8M Sell
784,282
-4,654
-0.6% -$215K 0.05% 166
2020
Q3 		$30.3M Buy
788,936
+14,949
+2% +$595K 0.04% 169
2020
Q2 		$33.4M Buy
773,987
+67,072
+9% +$2.54M 0.05% 143
2020
Q1 		$18.4M Buy
706,915
+161,859
+30% +$4.7M 0.04% 178
2019
Q4 		$17M Buy
+545,056
New +$16.1M 0.03% 248

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company's YMAB Position: Q2 2021 in Review

Loomis, Sayles & Company sold out of Y-mAbs Therapeutics (YMAB) in Q2 2021, closing a stake of 782,084 shares — an estimated $23.6M sold.

Loomis, Sayles & Company first reported a position in YMAB in Q4 2019 and held it in 6 quarters. The position peaked at $38.8M in Q4 2020. 100 funds tracked by Wall St. Rank hold YMAB as of Q2 2021.

  • Loomis, Sayles & Company reported no remaining Y-mAbs Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 782,084 Y-mAbs Therapeutics shares in Q2 2021, an estimated $23.6M.
  • Loomis, Sayles & Company first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 6 quarters.
  • Loomis, Sayles & Company's Y-mAbs Therapeutics position peaked at $38.8M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2021.

Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.